business / news / / Boston.com
Eli Lilly will acquire Boston-based cancer biotech Kelonia Therapeutics for $7 billion.
Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront.
KEY POINTS
- Kelonia is developing an in vivo cell therapy platform for blood cancers, including multiple myeloma.
- Kelonia's platform could enable off-the-shelf gene therapies, mitigating manufacturing and access barriers.
- Eli Lilly has recently acquired Centessa Pharmaceuticals and Orna Therapeutics, expanding its Boston footprint.
COMPANIES
Summarized by Newsio from Boston.com. How we summarize →